A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements

Jonathan Riess, Sukhmani K. Padda, Charles D. Bangs, Millie Das, Joel W. Neal, Adour R. Adrouny, Athena Cherry, Heather A. Wakelee

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Tumors with c-ros oncogene 1 (ROS1) translocations are a newly discovered molecular subset of non esmall-cell lung cancer (NSCLC). Like anaplastic lymphoma receptor tyrosine kinase (ALK)-rearranged NSCLC, early phase clinical trials show a high response rate to crizotinib in these patients. Some retrospective studies suggest patients with ALKP tumorshave a longer progression-free survival (PFS) to pemetrexed compared with other chemotherapeutics- though this is controversial. Little is known about whether patients with ROS1-rearranged tumors preferentially respond to specific chemotherapy drugs. This small, retrospective case series suggests that some NSCLC patients whose tumors harbor the ROS1 gene rearrangements might have a lengthy PFS using pemetrexed-containing therapy. In clinical practice, oncologists might want to consider pemetrexed-containing regimens when chemotherapy is indicated.

Original languageEnglish (US)
Pages (from-to)592-595
Number of pages4
JournalClinical Lung Cancer
Volume14
Issue number5
DOIs
StatePublished - Sep 2013
Externally publishedYes

Keywords

  • Chemotherapy
  • Molecular subtypes
  • NSCLC
  • Pemetrexed
  • ROS1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'A case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non-small-cell lung cancer patients harboring ros1 gene rearrangements'. Together they form a unique fingerprint.

  • Cite this